Blue Trust Inc. Raises Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Blue Trust Inc. boosted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 27.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,430 shares of the company’s stock after buying an additional 3,071 shares during the period. Blue Trust Inc.’s holdings in Takeda Pharmaceutical were worth $205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of TAK. Public Employees Retirement System of Ohio acquired a new stake in Takeda Pharmaceutical in the third quarter valued at approximately $601,000. Verition Fund Management LLC acquired a new stake in shares of Takeda Pharmaceutical in the 3rd quarter worth $1,533,000. HighTower Advisors LLC increased its position in Takeda Pharmaceutical by 199.5% during the 3rd quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock valued at $1,744,000 after buying an additional 81,653 shares in the last quarter. XTX Topco Ltd purchased a new stake in Takeda Pharmaceutical in the third quarter valued at about $957,000. Finally, Creative Planning boosted its holdings in Takeda Pharmaceutical by 46.3% in the third quarter. Creative Planning now owns 157,630 shares of the company’s stock worth $2,242,000 after acquiring an additional 49,871 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

TAK opened at $13.33 on Wednesday. The company has a market cap of $42.40 billion, a P/E ratio of 33.31, a price-to-earnings-growth ratio of 0.23 and a beta of 0.51. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The firm’s 50-day moving average price is $13.31 and its 200-day moving average price is $13.89. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, equities analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.